Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE versus VIMOVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE versus VIMOVO.
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE vs VIMOVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a centrally acting opioid analgesic that binds to mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant that may enhance analgesia.
VIMOVO (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever. Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase in gastric parietal cells. The combination is intended to reduce the risk of NSAID-associated gastric ulcers.
1-2 capsules orally every 4-6 hours as needed; maximum 6 capsules per day. Each capsule contains propoxyphene hydrochloride 65 mg, aspirin 325 mg, and caffeine 32.4 mg.
One tablet (naproxen 500 mg/esomeprazole 20 mg) orally twice daily.
None Documented
None Documented
Propoxyphene: 6-12 hours (up to 36 hours in overdose); norpropoxyphene: 30-36 hours. Aspirin: 2-3 hours for low doses, up to 15-30 hours in overdose. Caffeine: 3-6 hours; prolonged in liver disease.
Naproxen: 12-17 hours (prolonged in elderly and renal impairment; dosing interval typically 12 hours). Esomeprazole: 1-1.5 hours (metabolized by CYP2C19 and CYP3A4; no accumulation after repeated dosing).
Renal elimination of propoxyphene and its metabolites (mainly norpropoxyphene) accounts for approximately 70-90% of the dose; fecal excretion is minimal (<10%). Aspirin is renally eliminated as salicylates (75-90% as conjugates, 10% free), while caffeine is primarily metabolized and its metabolites are excreted renally.
Renal 50% as naproxen metabolites, <1% unchanged naproxen; less than 1% excreted unchanged in feces as esomeprazole; esomeprazole metabolites excreted in urine 80% and feces 20%.
Category D/X
Category C
NSAID / Antiplatelet
NSAID/PPI Combination